Better Health. Better Life.

M Pharmaceutical Inc. Appoints President Of U.S. Operating Company Based In Greater Cincinnati

VANCOUVER, B.C., CANADA (August 2, 2016) – M-Pharmaceutical Inc., (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the "Company" or “M Pharma”), announced it has appointed Mr. Gary Thompson of Fort Thomas, Kentucky to serve as President of the Company’s wholly owned subsidiary, M Pharmaceutical USA Inc., and oversee the production, testing and regulatory approval program for M Pharmaceutical’s C-103 project, M Pharmaceutical’s recently acquired reformulated Orlistat drug technology. 

Mr. Brian Keane, President of the M Pharmaceutical Inc. noted that “Gary has been intimately involved in the creation of C-103, and has the experience to oversee the various steps needed over the next twelve to twenty four months to get this drug to market.  We look forward to working with him to achieve this goal.”

Gary A. Thompson, President of M-Pharmaceutical U.S.A. Inc., has over 30 years of sales and management experience in Fortune 500 health care organizations and start up pharmaceutical companies. He has served as Vice President of sales for Cigna Healthcare managing billions of assets over his career. Most recently, he has had management and leadership roles at several start up ventures that have obtained issued patents for innovative technology, including ToConceive LLC. (FDA approved) in women's health and wellness and in the obesity space as president of Chelatexx LLC, from whom the Company acquired its C-103 reformulated Orlistat. He is a graduate of Northern Kentucky University, with a BS in Kinesiology. Gary is also a director of 501(c)(3) Non-Profit organization, Nehemiah Vision Ministries based in Chambrun, Haiti.

 “The experience of the team and the resources that M-Pharmaceutical Inc. provides will allow us to expand our efforts to make C-103 available to the many people whom it can benefit greatly,” said Mr. Thompson. “I am excited to contribute my leadership to the company in order to bring this drug technology to market and make a difference in the lives of so many people.”

About M-Pharmaceutical Inc.
Formed in early 2015, M-Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management.  In addition to its recent acquisition of C-103, a reformulation of Orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. 

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:
Investor Relations
Phone: +1 604 428 0511          
info@m-pharma.ca
www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to its biomedical technologies.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.